|
|
|
| Effects of Mouse Nerve Growth Factor Combined with Adenosine Cobalt on Serum ESM-1, ET-1, MBP and Hcy in Patients with Diabetic Peripheral Neuropathy |
| SANG Yiquan, SUN Yan, WANG Ben |
| Xuzhou Central Hospital, Jiangsu Xuzhou 221009, China |
|
|
|
|
Abstract Objective: To investigate the effects of mouse nerve growth factor combined with adenosine cobalt on diabetic peripheral neuropathy in patients with clinical efficacy and serum on endothelial cell specific molecule -1 (ESM-1), endothelin -1 (ET-1), myelin basic protein (MBP) and homocysteine (Hcy) level of influence. Methods: 90 patients of diabetic peripheral neuropathy sdmitted in our hospital from April 2016 to July 2017 were selected as research objects. The two groups were treated with Mouse Nerve Growth Factor for Injection after their examination. On this basis, the observation group added adenosine cobalamin injection. Dynamic monitoring and analysis of clinical efficacy of two groups of patients before and after treatment, TSS (neuropathy symptoms questionnaire), TCSS (Toronto clinical scoring system) and VAS (visual analogue scale) score, observation of the two groups of patients with serum ESM-1, ET-1, MBP, Hcy level and nerve conduction velocity. Results: After treatment, the total effective rate of the observation group was 86.67% (39/45) superior to that of the control group (68.89% (31/45) (P < 0.05). The scores of TSS, TCSS and VAS in the observation group were all lower than those in the control group (P < 0.05). The serum levels of ESM-1, ET-1, MBP and Hcy in the observation group were lower than those in the control group (P < 0.05). The MNCV and SNCV of the tibial nerve and median nerve in the observation group increased significantly, and the conduction velocity was better than that of the control group (P < 0.05). Conclusion: The combination of mouse nerve growth factor and adenosine cobalamin can improve the clinical efficacy and nerve conduction velocity, and decrease serum ESM-1, ET-1, MBP and Hcy levels, as well as TSS, TCSS and VAS scores.
|
|
|
|
|
|
[1] 陆祖谦,丁维.糖尿病周围神经病变诊治进展[J].药品评价,2013,17(10):35~42,45.
[2] 率红莉,汪津洋.糖尿病周围神经病变治疗药物研究进展[J].中国药房,2014,4(25):377~382.
[3] Feldman EL, Nave KA, Jensen TS,et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain[J].Neuron,2017,93(6):1296~1313.
[4] 常荣,朱英标,丁莉,陈日秋.鼠神经生长因子联合α-硫辛酸治疗糖尿病周围神经病变的临床观察[J].中国临床药理学杂志,2014,10(30):892~894,900.
[5] 赫广玉,孙成林,刘玉佳,潘信,王桂侠.糖尿病周围神经病变神经损害特点及相关因素分析[J].中国糖尿病杂志,2014,2(22):118~121.
[6] Leishear K, Ferrucci L, Lauretani F, et al. Vitam in B12 and hom ocys-teine levels and 6-year change in peripheral nerve function and neuro-logical signs[J].Gerontol A Biol Sci M ed Sci, 2012 , 67(5): 537~543.
[7] 王秀阁,韩笑.糖尿病周围神经病变诊疗现状[J].中医临床研究,2016,20(8):142~145.
[8] 李媛媛,沈薇薇,袁硕.同型半胱氨酸对糖尿病周围神经病变影响的研究进展[J].大众科技,2015,197(17):72~74.
[9] 董琪;李全民.糖尿病周围神经病变发病机制的研究进展[J].现代仪器与医疗,2015,2(21):20~21,34.
[10] W ile DJ, Toth C. Association of m etform in, elevated hom ocysteine, andm ethylm alonic acid levels and clinically worsened diabetic peripheralneuropathy[J]. Diabetes Care, 2010, 33(1): 156~161. |
|
|
|
2018, Vol. 24 
